The Motley Fool, founded in 1993 by brothers David and Tom Gardner, is a multimedia financial services company dedicated to empowering individual investors with accessible, actionable advice. Headquartered in Alexandria, Virginia, the company offers a range of products, including stock recommendations, investment research, and personal finance guidance, through its popular website, newsletters, podcasts, and premium subscription services.
This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results One clinical-stage biotech is defying gravity—here’s why its record-breaking run is catching institutional attention.
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.
2 Unstoppable Growth Stocks I'd Buy Now Both of these electric air taxi pioneers have sold off hard recently, creating a potential entry point for patient investors.
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.
GEO Shares Down 44% as Fund Sells $9 Million in Stock Amid ICE Allegations and Softer Outlook GEO’s latest quarter shows a company pulling in record contracts while wrestling with litigation and cooling earnings guidance—here’s what investors need to know.
Why One Fund Made a $59 Million Bet on Semtech Stock as Shares Surge to Multi-Year Highs Semtech’s turnaround is gaining momentum—and one fund just made a sizable bet on what comes next.
Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers.
Here's Why One Fund Just Bet $46 Million on This Surging Printed Circuit Board Stock One semiconductor supplier’s surge in institutional demand is revealing where smart money expects the next leg of tech growth to unfold.
This Small-Cap Consumer Stock Has Landed New Institutional Backing as Shares Surge 60% A fast-growing niche segment may be the real reason this small-cap consumer products stock is drawing new institutional attention.
Private Equity-Style Fund Buys $15.7 Million in Harrow Stock as Revenue Jumps 45% Harrow’s accelerating revenue and expanding product portfolio may help explain why a fundamentals-focused investment firm just made it a new position.
This Fund Leaned Into 2025's Big Biotech Rally with a $9.5 Million Bet on Mineralys One small fund’s high-conviction move offers a window into how specialists are navigating 2025’s biotech rally.
3 Vanguard ETFs I'd Buy Right Now These three low-cost funds offer exposure to international dividends, U.S. technology, and small-cap value -- the building blocks of a diversified portfolio.
Why This Private Equity-Style Fund Just Bet $17 Million on Lumen Technologies Stock One small-cap specialist just made a surprisingly large bet on one of telecom’s most complicated turnarounds.
Penn Capital Unwinds $17.1 Million BGC Stake as Broker Posts 31% Revenue Surge This private-equity-style shop trimmed its position in a financial technology firm that's posting record numbers despite a steep stock decline.
Ford's Overlooked Profit Machine Is Under Attack by Rival Ford has a serious profit machine that many investors overlook, but a close rival is catching on and gearing up for an offensive.
Why AMD's Impressive Growth Is Just Getting Started AMD's revenue growth has been improving of late, and its CEO expects that trend to continue for years.
Nvidia's Latest Beat Proves AI Isn't Cooling Off Yet, but Is the Chipmaker Still the Best AI Play? The GPU leader delivered better-than-expected results, and its guidance suggests that its impressive growth is not over.
10 AI Stocks I'd Buy Right Now Artificial intelligence (AI) stocks have sold off significantly over the past 30 days, and while some names remain overvalued, several appear to be bargains for long-term investors.
Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029 The mid-cap biotech could become a notable player in the industry's hottest therapeutic area.
5 Smart Moves That Make Your 0% APR Window Actually Worth It Use these five smart habits like picking a long 0% period, automating payments, and avoiding new debt to get the most out of your 0% APR window.
The Best Cryptocurrency to Buy With $1,000 Right Now Bitcoin's price has slumped in recent months, which could make it a good time to buy.
History Says Now Is the Perfect Time to Buy Meta Stock Meta Platforms has sold off heavily following its spending plan announcement.
Billionaire Investor Bill Ackman Says This 1 Stock Could Be a Long-Term Compounder Earlier this year, Bill Ackman's fund took a large stake in a company that it views as a free cash flow machine with significant earnings growth ahead.
Great News for Nvidia Stock Investors! Nvidia stock investors can celebrate these developments.
Should Investors Close the Door on Opendoor? The iBuyer is reinventing itself under new leadership, but the business model still leaves much to be desired.
Where Will Vertex Pharmaceuticals Be in 5 Years Prediction: Vertex will be much larger by the end of the decade.
How Has Amazon Stock Done for Investors? Investors should avoid making decisions about this stock based on a single time horizon.
